P. Traxler

发表

Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones.

P. Traxler, J. Green, H. Mett, 1999, Journal of medicinal chemistry.

Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.

P. Furet, N. Lydon, P. Traxler, 1997, Journal of medicinal chemistry.

ATP site‐directed competitive and irreversible inhibitors of protein kinases

P. Traxler, C. García-echeverría, D. B. Evans, 2000, Medicinal research reviews.

4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.

P. Furet, N. Lydon, P. Traxler, 1996, Journal of medicinal chemistry.

Strategies toward the design of novel and selective protein tyrosine kinase inhibitors.

P. Furet, P. Traxler, P Furet, 1999, Pharmacology & therapeutics.

Tyrosine kinase inhibitors: From rational design to clinical trials

Pascal Furet, Guido Bold, Giorgio Caravatti, 2001, Medicinal research reviews.

Molecular approaches to receptors as targets for drug discovery.

P. Traxler, C. García-echeverría, D. B. Evans, 2000, EXS.

Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase.

N. Lydon, P. Traxler, T. Meyer, 1992, Cancer research.

Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors.

N. Lydon, P. Traxler, T. Meyer, 1990, The Journal of biological chemistry.

A potent protein‐tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor‐expressing tumor cells in vitro and in vivo

R. Cozens, N. Lydon, P. Traxler, 1998 .

4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.

P. Traxler, H. Mett, E. Buchdunger, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

A potent protein‐tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor‐expressing tumor cells in vitro and in vivo. Int. J. Cancer, 76, 154–163 (1998)

R. Cozens, N. Lydon, P. Traxler, 1999, International journal of cancer.

A strategy for screening anti‐tumor drugs utilizing oncogenes encoded in retroviral vectors

T. Roberts, N. Lydon, P. Traxler, 1996, International journal of cancer.

Advances in Brief Imatinib Mesylate Is a Potent Inhibitor of the ABCG 2 ( BCRP ) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro

P. Houghton, P. Traxler, E. Buchdunger, 2004 .

Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro

P. Houghton, P. Traxler, E. Buchdunger, 2004, Cancer Research.

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

G. Martiny-Baron, K. Altmann, R. Cozens, 2000, Journal of medicinal chemistry.

Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases

P. Traxler, M. Lang, M. Ramachandra, 2016, Molecular Cancer Therapeutics.

Sulfonylbenzoyl-nitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase.

N. Lydon, P. Traxler, T. Meyer, 1991, Journal of medicinal chemistry.

[(Alkylamino)methyl]acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase.

N. Lydon, P. Traxler, H. Mett, 1995, Journal of medicinal chemistry.

Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.

I. Fidler, P. Traxler, E. Buchdunger, 2000, Cancer research.

Antineoplastic agents 31. Oenothera caespitosa.

P. Traxler, C. Pase, G. R. Pettit, 1973, Lloydia.

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

J. Mestan, D. Fabbro, H. Lane, 2004, Cancer research.

Tyrosine kinases as targets in cancer therapy – successes and failures

P. Traxler, Peter Traxler, 2003, Expert opinion on therapeutic targets.

Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.

I. Fidler, P. Traxler, E. Buchdunger, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity.

N. Lydon, P. Traxler, H. Mett, 1994, Proceedings of the National Academy of Sciences of the United States of America.

AEE788

J. Mestan, D. Fabbro, H. Lane, 2004, Cancer Research.

Stress signaling boosts interferon-induced gene transcription in macrophages

C. Bock, J. Arthur, P. Traxler, 2022, Science Signaling.

Isolation and structural elucidation of 3,6-dioxo-hexahydro-pyrrolo [1,2-a]-pyrazine from the echinodermLuidia clathrata

P. Traxler, R. Dreele, G. Pettit, 1973, Experientia.

Tyrosine kinase targets in drug discovery

P. Traxler, Peter Traxler, Konstantina Grosios, 2003 .

Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.

N. Lydon, P. Traxler, H. Mett, 1997, Journal de pharmacie de Belgique.

Tyrosine kinase inhibitors: From rational design to clinical trials

J. Wood, P. Furet, P. Traxler, 2001, Medicinal research reviews.

Tyrosine kinases as targets in cancer therapy – successes and failures

P. Traxler, 2003, Expert opinion on therapeutic targets.

Pyrrolo[2,3-d]pyrimidine and Pyrazolo[3,4-d]pyrimidine Derivatives as Selective Inhibitors of the EGF Receptor Tyrosine Kinase

P. Furet, R. Cozens, N. Lydon, 2001 .

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis

Stover, Roth, J. Mestan, 2000, Journal of medicinal chemistry.